Peptides DSIP 5 mg

DSIP

Reduces the basal level of corticotropin and blocks its release. Stimulates the release of luteinizing hormone (LH). It stimulates the release of somatoliberin and the secretion of somatotrophin and inhibits the secretion of somatostatin.  

Roles in physiological processes

• Can act as a stress limiting factor. 
• Can have a direct or indirect effect on body temperature and relieve hypothermia.
• Can normalize blood pressure and myocardial contraction. It was shown that it increases the efficiency of oxidative phosphorylation in rat mitochondria in vitro, which suggests that it can have an antioxidant effect
• There are also conflicting data regarding the ego's involvement in sleep patterns.  and suppression of paradoxical sleep (PS), while some studies do not show any correlation. A stronger effect on sleep was noted for synthesized analogs of DSIP.

It can influence the function of epithelial cells of the human lens through the MAPK pathway, which is involved in cell proliferation, differentiation, motility, survival, and apoptosis.

Roles in illness and medicine

It was found that it has anticarcinogenic properties. In a study on mice, injection of the drug DSIP during the life of the mice reduced the overall frequency of spontaneous tumors by 2.6 times.

The same study showed that it also has a geroprotective effect: it slows down the age-related shutdown of estrous function;  it reduced the frequency of chromosome aberrations in bone marrow cells by 22.6% and increased the maximum lifespan by 24.1% compared to the control group.

DSIP levels may be significant in patients diagnosed with major depressive disorder (MDD). In several studies, DSIP levels in plasma and cerebrospinal fluid have been significantly abnormal in patients with MDD, although there is controversy as to whether levels are found to be higher or lower than in healthy controls. 

Studies have shown a direct link between the expression of GILZ (homologous DSIP) and adipogenesis, which is associated with obesity and metabolic syndrome.

In studies in rats with metaphyte-induced epilepsy, DSIP acted as an anticonvulsant, significantly reducing the frequency and duration of seizures, suggesting DSIP as a potential treatment for epilepsy.

DSIP has been found to have an analgesic effect. In studies on mice, it has been found to have a strong antinociceptive effect when administered intracerebroventricularly or intracisternally (see Method of administration). 

Because of its possible effects on sleep and nociception, trials were conducted to determine whether DSIP could be used as an anesthetic agent. One such study found that administering DSIP to humans as an adjunct to isoflurane anesthesia actually increased the heart rate and decreased the depth of anesthesia, rather than deepening it as expected.

Low concentrations of DSIP in plasma were found in patients with Cushing's syndrome.  DSIP levels have been found to be slightly elevated in Alzheimer's patients, although this is unlikely to be the cause. 

The DSIP drug, Deltaran, was used to correct the function of the central nervous system in children after antiblastoma therapy. Ten children between the ages of 3 and 16 underwent a ten-day course of Deltaran and recorded their bioelectrical activity. It was found that chemotherapy-induced bioelectrical activity in 9 out of 10 children decreased with the introduction of DSIP. 

DSIP can act antagonistically on opiate receptors to significantly inhibit the development of opioid and alcohol addiction, and is currently being used in clinical trials to treat withdrawal syndrome. In one of these studies, it was reported that 97% of opiate-dependent and 87% of alcohol-dependent patients had symptoms relieved by DSIP administration. 

In some studies, the use of DSIP alleviated narcolepsy and normalized sleep disturbances. The safety and possible side effects of long-term use of DSIP have not been established in clinical studies.